# name
Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

# metadata.dc.description.abstract[].value
Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFα) inhibitors or anakinra.1–6 However, this therapeutic arsenal is unable to control the disease in all patients.#N##N#Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, has been successfully used in two patients with refractory adult-onset Still’s disease.7 As the similarity of clinical and laboratory features present in SOJIA and adult-onset Still’s disease implies that these conditions have similar …

# metadata.dc.relation.ispartof[].value
Annals of the Rheumatic Diseases, 2009, vol. 68, num. 4, p. 607-608

# metadata.dc.source[].value
Articles publicats en revistes (Ciències Clíniques)

# metadata.dc.title[].value
Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.